Rodman & Renshaw Initiates Coverage on MediciNova (MNOV) with an Outperform
More News related to MNOV
- MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MediciNova, Inc. Appoints Mr. Hiroaki Shigeta to Its Board of Directors
- Notable Mergers and Acquisitions of the Day 8/21: MNOV/AVGN, BMY/MEDX, ORCL/JAVA
- MediciNova (MNOV) To Aquire Avigen (AVGN) For $1.24/Share
- Unusual 11 Mid-Day Movers 7/21: MNOV, JRN, JDAS, BCRX Higher; CIT, IDIX, STSA, LXK Lower
More News related to New Coverage
- Morgan Stanley Initiates Coverage on Williams Companies (WMB) with an Overweight
- Morgan Stanley Starts ONEOK (OKE) at Underweight, $40 Price Target
- Broadpoint.Amtech Initiates Coverage on Willbros Group (WG) with a Buy; Leading North American Pipeline Contractor
- Miller Tabak Initiates Coverage on Oclaro (OCLR) with a Buy
- Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
Rodman & Renshaw initiates coverage on MediciNova (Nasdaq: MNOV) with an Outperform. Price target $9.
MediciNova, Inc. is a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the United States market.
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
